Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers
ViPOR Combination
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
What the film says
Most children with B-cell leukemia are cured. For those who relapse twice, or relapse after transplant, or after CAR T therapy, the path narrows quickly.
The idea: a CAR T cell that recognizes two leukemia markers at once, built for children.
CD19 CAR T cells can fail when the leukemia stops displaying CD19. At Children's Hospital Colorado, a child's own T cells receive a receptor that binds both CD19 and CD22, so the leukemia has to lose both to escape. The cells are made in the university's own manufacturing facility, and given once after chemotherapy makes room.
Heavy and light disease are studied in parallel, from three months to age thirty, with careful dose escalation. Vanessa Fabrizio leads it. Public record; not medical advice.
Sources behind this film
Eligibility: ≥2 relapses, relapse after BMT, relapse after single-antigen CAR T, refractory; CD19 antigen loss as escape mechanism; Autologous CD19xCD22 CAR T made at the Gates Biomanufacturing Facility; Lymphodepletion then infusion (+2 more lines)
The drug
The investigational product is an autologous, genetically modified CD19xCD22 CAR T cell product produced by the Gates Biomanufacturing Facility.
This is an open-label Phase I trial consisting of 2 cohorts to determine the safety and tolerability of CD19x22 CAR T in Pediatric Patients with R/R B-ALL.
This trial will include two parallel cohorts based on disease burden prior to lymphodepleting chemotherapy, Cohort 1: high disease burden cohort: defined as >=25% bone marrow lymphoblasts and/or non-CNS extramedullary disease, and Cohort 2: low disease burden cohort: defined as <25% bone marrow lymphoblasts and no non-CNS extramedullary disease. Dose escalation will proceed independently within each cohort using the Bayesian Optimal Interval (BOIN) design.
The study
This study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.